# 4D Molecular Therapeutics, Inc. (FDMT) operating margin

URL: https://funkfolio.com/stock/FDMT/operating-margin

> 4D Molecular Therapeutics, Inc. (FDMT) operating margin was -187.2% in fiscal 2025, up 507491.1 points from fiscal 2024.

---

## 4D Molecular Therapeutics, Inc. (FDMT) operating margin

**Operating margin · fiscal 2025:** -187.2% year ended Dec 31, 2025

4D Molecular Therapeutics, Inc. (FDMT) had an operating margin of -187.2% in fiscal 2025 (the year ended December 31, 2025). That is 507491.1 percentage points higher than the -507678.4% of fiscal 2024. Figures as of 17 Nov 2026, 21:24 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Operating margin, fiscal 2025:** -187.2%
- **Change on fiscal 2024:** +507491.1 pts
- **Highest on record:** -187.2% fiscal 2025
- **Lowest on record:** -507678.4% fiscal 2024
- **Fiscal years on record:** 7 2019–2025

Figures as of 17 Nov 2026, 21:24 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

### 4D Molecular Therapeutics, Inc. operating margin, in more detail

Across the 7 fiscal years on record (2019–2025), the highest was -187.2% in fiscal 2025 and the lowest -507678.4% in fiscal 2024. The fiscal 2025 figure is higher than in every one of the 6 earlier fiscal years on record, whose median is -637.0%.

Net margin was -164.4% in fiscal 2025.

### Operating margin by fiscal year

- Operating margin
- Net margin

### 4D Molecular Therapeutics, Inc. operating margin, year by year

4D Molecular Therapeutics, Inc. (FDMT) operating margin by fiscal year

| Fiscal year | Operating margin | Change | Year ended | Net margin |
| --- | --- | --- | --- | --- |
| 2025 | -187.2% | 507491.1 pts up | Dec 31, 2025 | -164.4% |
| 2024 | -507678.4% | 507133.7 pts down | Dec 31, 2024 | -434778.4% |
| 2023 | -544.6% | 2971.9 pts up | Dec 31, 2023 | -486.6% |
| 2022 | -3516.5% | 3121.1 pts down | Dec 31, 2022 | -3435.4% |
| 2021 | -395.5% | 28.6 pts up | Dec 31, 2021 | -395.4% |
| 2020 | -424.0% | 305.3 pts up | Dec 31, 2020 | -424.3% |
| 2019 | -729.4% | — | Dec 31, 2019 | -708.4% |

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

### How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

### 4D Molecular Therapeutics, Inc., figure by figure

- [4D Molecular Therapeutics, Inc. market cap](https://funkfolio.com/stock/FDMT/market-cap)
- [4D Molecular Therapeutics, Inc. revenue](https://funkfolio.com/stock/FDMT/revenue)
- [4D Molecular Therapeutics, Inc. earnings](https://funkfolio.com/stock/FDMT/earnings)
- [4D Molecular Therapeutics, Inc. earnings per share (EPS)](https://funkfolio.com/stock/FDMT/eps)
- [4D Molecular Therapeutics, Inc. P/E ratio](https://funkfolio.com/stock/FDMT/pe-ratio)
- [4D Molecular Therapeutics, Inc. P/S ratio](https://funkfolio.com/stock/FDMT/ps-ratio)
- [4D Molecular Therapeutics, Inc. P/B ratio](https://funkfolio.com/stock/FDMT/pb-ratio)
- [4D Molecular Therapeutics, Inc. free cash flow](https://funkfolio.com/stock/FDMT/free-cash-flow)
- [4D Molecular Therapeutics, Inc. dividend](https://funkfolio.com/stock/FDMT/dividend)
- [4D Molecular Therapeutics, Inc. shares outstanding](https://funkfolio.com/stock/FDMT/shares-outstanding)
- [4D Molecular Therapeutics, Inc. total debt](https://funkfolio.com/stock/FDMT/total-debt)
- [4D Molecular Therapeutics, Inc. cash on hand](https://funkfolio.com/stock/FDMT/cash)
- [4D Molecular Therapeutics, Inc. total assets](https://funkfolio.com/stock/FDMT/total-assets)
- [4D Molecular Therapeutics, Inc. return on equity (ROE)](https://funkfolio.com/stock/FDMT/roe)
- [4D Molecular Therapeutics, Inc. return on invested capital (ROIC)](https://funkfolio.com/stock/FDMT/roic)

[4D Molecular Therapeutics, Inc. (FDMT) overview: price, valuation and scorecard](https://funkfolio.com/stock/FDMT)

### 4D Molecular Therapeutics, Inc. operating margin: questions and answers

**What is 4D Molecular Therapeutics, Inc.'s operating margin?**

4D Molecular Therapeutics, Inc. (FDMT) had an operating margin of -187.2% in fiscal 2025 (the year ended December 31, 2025). That is 507491.1 percentage points higher than the -507678.4% of fiscal 2024.

**Is 4D Molecular Therapeutics, Inc.'s operating margin high or low compared with its own history?**

The fiscal 2025 figure is higher than in every one of the 6 earlier fiscal years on record, whose median is -637.0%.

**What are the highest and lowest operating margin figures on record for 4D Molecular Therapeutics, Inc.?**

Across the 7 fiscal years on record (2019–2025), the highest was -187.2% in fiscal 2025 and the lowest -507678.4% in fiscal 2024.

**What are 4D Molecular Therapeutics, Inc.'s gross and net margins?**

Net margin was -164.4% in fiscal 2025.

**How is 4D Molecular Therapeutics, Inc.'s operating margin calculated?**

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

Fiscal years are named for the calendar year they end in.

### Learn: operating margin

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “4D Molecular Therapeutics, Inc. (FDMT) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/FDMT/operating-margin

Underlying data: the company's filings with the SEC and Yahoo Finance.
